Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Guillermo Garcia‐Manero, Farhad Ravandi et al.|Leukemia Research|2018Cited by 9
Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent FailureKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|Blood|2022Cited by 0